Evaxion Biotech A/S (EVAX)
EVAX Stock Price Chart
Explore Evaxion Biotech A/S interactive price chart. Choose custom timeframes to analyze EVAX price movements and trends.
EVAX Company Profile
Discover essential business fundamentals and corporate details for Evaxion Biotech A/S (EVAX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Feb 2021
Employees
46.00
Website
https://www.evaxion-biotech.comCEO
Helen Katrina Tayton-Martin
Description
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
EVAX Financial Timeline
Browse a chronological timeline of Evaxion Biotech A/S corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 20 Aug 2026
EPS estimate is -$0.01, while revenue estimate is $6.70m.
Earnings released on 7 May 2026
EPS came in at -$0.44 falling short of the estimated -$0.01 by -4.30k%.
Earnings released on 5 Mar 2026
EPS came in at -$1.00 falling short of the estimated -$0.25 by -308.16%.
Earnings released on 6 Nov 2025
EPS came in at $0.73 , while revenue for the quarter reached $7.49m .
Earnings released on 14 Aug 2025
EPS came in at -$0.76 falling short of the estimated -$0.50 by -52.00%, while revenue for the quarter reached $37.00k , missing expectations by -99.54%.
Earnings released on 27 May 2025
EPS came in at -$0.29 surpassing the estimated -$0.65 by +55.38%.
Earnings released on 26 Mar 2025
EPS came in at -$0.80 falling short of the estimated -$0.26 by -207.69%, while revenue for the quarter reached $122.00k , missing expectations by -92.65%.
Stock split effective on 14 Jan 2025
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Oct 2024
EPS came in at -$0.20 surpassing the estimated -$0.60 by +66.67%, while revenue for the quarter reached $3.02m , beating expectations by +81.80%.
Earnings released on 14 Aug 2024
EPS came in at -$0.60 falling short of the estimated $0.10 by -700.00%, while revenue for the quarter reached $154.00k , beating expectations by +28.33%.
Earnings released on 28 May 2024
EPS came in at $0.15 surpassing the estimated -$0.56 by +126.79%, while revenue for the quarter reached $51.00k , beating expectations by +27.50%.
Earnings released on 27 Mar 2024
EPS came in at -$0.80 surpassing the estimated -$1.60 by +50.00%, while revenue for the quarter reached $73.00k .
Stock split effective on 22 Jan 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 19 Dec 2023
EPS came in at -$10.50 falling short of the estimated -$0.19 by -5.43k%.
Earnings released on 18 Aug 2023
EPS came in at -$10.50 falling short of the estimated -$0.21 by -4.90k%.
Earnings released on 31 May 2023
EPS came in at -$12.00 falling short of the estimated -$0.24 by -4.90k%.
Earnings released on 27 Apr 2023
EPS came in at -$14.50 falling short of the estimated -$0.24 by -5.94k%.
Earnings released on 14 Nov 2022
EPS came in at -$12.00 surpassing the estimated -$17.00 by +29.41%.
Earnings released on 10 Aug 2022
EPS came in at -$10.00 surpassing the estimated -$16.50 by +39.39%.
Earnings released on 11 May 2022
EPS came in at -$12.50 surpassing the estimated -$17.50 by +28.57%.
Earnings released on 22 Mar 2022
EPS came in at -$19.50 falling short of the estimated -$15.00 by -30.00%.
Earnings released on 9 Nov 2021
EPS came in at -$0.27 surpassing the estimated -$0.34 by +20.59%.
Earnings released on 12 Aug 2021
EPS came in at -$0.36 falling short of the estimated -$0.29 by -24.14%.
EVAX Stock Performance
Access detailed EVAX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
